The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:montez sweat1000+rob lowe1000+tanner hudson500+frozen frenzy200+payton pritchard1000+huevo500+winter weather advisory2000+joão cancelo1000+

Category:All Headlines World & Geopolitics Markets & Economy Tech & AI PoliticsSearch results for: "Compass Pathways’ New 52-" (30 stories)

Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year

Lead StoryCompass Pathwaysgeneral

Sep 9

Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year

<a href="https://news.google.com/rss/articles/CBMi-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?oc=5" target="_blank">Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year</a>&nbsp;&nbsp;Compass Pathways

Read Full Story Related Trends

Google Trends & Trending Search Intelligence

Real-time search volume

1000+23m ago

montez sweat

Bears DE Montez Sweat suspended 2 days for drug violation

Filter stories

1000+33m ago

rob lowe

Daily Wire's 'Confession': Details Revealed For James Franco, Rob Lowe Film

Filter stories

500+33m ago

tanner hudson

Bengals tight end Tanner Hudson out for season with torn pec

Filter stories

200+33m ago

frozen frenzy

The top reason to watch every NHL team in the Frozen Frenzy

Filter stories

Search Results for "Compass Pathways’ New 52-"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed

New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose

Psychiatric Timesgeneral

Sep 9

New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNdURpZ0hRZG1Ka1BRTGlvakZ1UjZQQXFJaTFnS2hQcGNaYlo1SnViTWx4VWNTczFHWGhoaWw0ZGhpR3AtMmhZUkY4VGpnekY3SV8tVXJWV0JGd1hfcWcyXzVlajJidkZsNmdZZ1F6WTB5UE0wdXJMbkRXMFh5UnVLWTdnSTFaNi1CdHdmN0pkcHhVZUpON1JRanE3a1hmNnJrcEIyeEsyYkVNbUpfdVRXQ1o4WVNmUmlGZHd5M2dMZjNmeUhLSHlDb21QdXVnU3M?oc=5" target="_blank">New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose</a>&nbsp;&nbsp;Psychiatric Times

World News, Markets & Google Trends

Top Headline Story

Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year

Google Trends & Trending Search Intelligence

montez sweat

rob lowe

tanner hudson

frozen frenzy

Search Results for "Compass Pathways’ New 52-"

New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

Compass Pathways stock rises as 52-week data show lasting depression relief

COMPASS Pathways (NasdaqGS:CMPS) Stock Forecast &amp; Analyst Predictions

Psilocybin may help prevent chemo-induced nerve pain; Definium scores second FDA Breakthrough Therapy designation

Why Is Compass Pathways Stock Soaring Wednesday? - Compass Pathways (NASDAQ:CMPS)

Why is Compass Pathways stock surging 9% today?

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026

Compass Pathways Surges as One-Year Data Show Lasting Relief From Psilocybin Therapy

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Compass Pathways reports 52-week Phase 3 COMP005 results for COMP360

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training

Compass Pathways stock hits 52-week high at 12.48 USD

Oppenheimer reiterates Compass Pathways stock rating on trial data

Apple, Compass Pathways, Aritzia and more analyst calls of the week

This Psychedelic Biotech Stock Is Soaring After Trump Executive Order

Compass Pathways stock hits 52-week high at 14.77 USD

COMPASS Pathways stock gets new employee grants on Nasdaq

Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins

Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances

What New 26-Week COMP006 Data Mean for TRD, With Boadie Dunlop, MD

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026

Synthetic Psilocybin Improves Symptom Severity in Treatment-Resistant Depression

Is COMPASS Pathways plc (CMPS) Stock a Psychedelic Medicine Opportunity After Positive COMP360 Data?

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

Compass Pathways Clears Another Hurdle – Builds Stronger FDA Case For Its Much-Awaited Depression Therapy

CMPS Stock Climbs After-Hours: Analyst Sees Depression Drug Approval By H1 2027 Or Sooner After Strong Trial Data

COMPASS Pathways (NasdaqGS:CMPS) Stock Forecast & Analyst Predictions